Organization | Sharp HealthCare

Sharp HealthCare Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Founded: San Diego CA United States (1955)

Organization Overview

First Clinical Trial

2007

NCT00543608

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2024

Timeline

NOW

Now

Alternative names

Sharp HealthCare

Active Ingredients

Drugs in Phase 4 Trials (8)

caffeine (1 trial)

ceftaroline fosamil (teflaro) (1 trial)

daptomycin (cubicin) (1 trial)

ephedrine (1 trial)

immune globulin (human) (Gamastan) (2 trials)

losartan (cozaar) (1 trial)

manganese (1 trial)

vancomycin (Vancocin) (2 trials)

Drugs in Phase 3 Trials (2)

ampicillin (1 trial)

gentamicin (garamycin) (1 trial)

Drugs in Phase 2 Trials (1)

iclaprim (1 trial)

Drugs in Other Trials (1)

pd-0325901 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Bacteremia (Phase 4)

Communicable Diseases (Phase 4)

Coronavirus Infections (Phase 4)

Healthcare-Associated Pneumonia (Phase 2)

Infant, Newborn, Diseases (Phase 4)

Infections (Phase 4)

Labor Pain (Phase 4)

Pneumonia (Phase 2)

Pneumonia, Ventilator-Associated (Phase 2)

Severe Acute Respiratory Syndrome (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 10
# of Trial APIs: 12